Loading...
•
Sep 30
Cibus Q3 2025 Earnings Report
Cibus reported a net loss of $24.3 million in Q3 2025, with revenue of $615,000 and ongoing progress in strategic cost reductions and commercialization initiatives.
Key Takeaways
Cibus continued to make commercial and regulatory advances in gene-edited crop traits despite generating limited revenue. The company posted a reduced net loss versus the prior year and remains focused on streamlining operations and expanding strategic partnerships.
Revenue for Q3 2025 was $615,000, with a net loss of $24.3 million.
EPS for the quarter was -$0.44.
Cash and cash equivalents stood at $23.9 million, expected to fund operations into Q2 2026.
Significant progress reported in global regulatory approvals and commercial partnerships for Rice and Canola traits.
Cibus
Cibus
Forward Guidance
Cibus remains focused on reducing annual cash usage and advancing its partner-funded programs, aiming for initial LATAM Rice revenue by 2027 and broader commercialization beyond.
Positive Outlook
- On track to deliver HT traits to LATAM customers by end of 2025
- Initiated field trials in LATAM for commercial rice programs
- Received initial partner payment in Sustainable Ingredients segment
- Completed pre-commercial pilot runs for biofragrance products
- Streamlined operations including Oberlin facility consolidation
Challenges Ahead
- Continued net losses and low current revenue base
- Relying heavily on future partner funding for sustainable ingredients
- Ongoing need for additional financing to maintain operations past Q2 2026
- No revenue breakout provided by segment or geography this quarter
- Uncertainty remains in global regulatory timelines for commercialization